Markets & Finance

Heartflow posted Q2 2026 revenue of $64.1 million, up 48% year over year, and raised its full-year revenue target for the second time in 2026, from an original $218M–$222M range to $246M–$250M. The company remains unprofitable, reporting a GAAP net loss of $15.7 million for the quarter, with total operating expenses at 111% of revenue. The article also flags an unresolved discrepancy between the earnings release and the 10-Q on the U.S. versus international revenue split, and notes that the guidance increases alone do not confirm accelerating adoption or that the new targets will be met.

Valneva posted €64.0 million in product sales for the first half of 2026, down from €91.0 million a year earlier, with a net loss of €63.3 million driven partly by €14.2 million in IXCHIQ-related one-time manufacturing cancellation fees and inventory impairment. The company held €121.5 million in cash at June 30 and maintained its full-year product sales guidance of €135 million to €150 million, implying €71 million to €86 million in second-half sales are needed to meet the range. A separate development: the EMA validated the Marketing Authorization Application for the Pfizer-Valneva Lyme disease vaccine candidate on August 14, beginning the formal assessment process with no decision date yet established.